Oral Semaglutide: New Formulation Aims to Reduce Dosing Strength for Diabetes Treatment
Background
Type 2 Diabetes Mellitus (T2DM) management often involves GLP-1 receptor agonists like semaglutide, which have demonstrated significant efficacy in glycemic control and weight loss. While injectable semaglutide is widely available, an oral formulation offers enhanced patient convenience and adherence. The current oral semaglutide tablet, Rybelsus, utilizes an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl]amino)caprylate (SNAC), to facilitate gastric absorption. However, optimizing formulation components beyond SNAC can further improve bioavailability, potentially allowing for reduced active pharmaceutical ingredient (API) dosage while maintaining therapeutic effect. This study addresses the need for a more efficient oral semaglutide delivery system.
Study Design
This randomized, open-label study will compare the pharmacokinetics of two oral semaglutide tablet formulations in healthy participants. The current formulation contains 300 mg SNAC and three helping agents, while the new formulation contains 300 mg SNAC and only one helping agent. Participants will receive one tablet daily over 4 weeks in each of three treatment periods, totaling 12 weeks of treatment. Dosing occurs in the morning after an overnight fast of at least 6 hours, with 120 mL of water, and no water 2 hours before or 30 minutes after dosing. Breakfast is permitted 30-45 minutes post-dose. The primary endpoint is the systemic uptake of semaglutide.
Results
This study's primary objective is to determine if the dosage strength of semaglutide in a new oral tablet formulation can be reduced compared to the current formulation. > The core measurement will be the systemic uptake of semaglutide in the body from both the current and new tablet formulations, each tested at three different dosage strengths. This pharmacokinetic comparison aims to assess bioequivalence or improved bioavailability, potentially allowing for lower active pharmaceutical ingredient (API) content per tablet while achieving similar therapeutic exposure. The study will quantify semaglutide concentrations in the blood using pharmacokinetic (PK) analysis to compare absorption profiles across the different formulations and strengths. The goal is to identify a new formulation that maintains or improves GLP-1R activation potential with a lower dose.
Key Findings
- Study aims to determine if new oral semaglutide formulation allows for reduced dosage strength.
- Compares systemic uptake of semaglutide from current vs. new tablet formulations.
- Each formulation will be tested at three different dosage strengths.
- Pharmacokinetic analysis will assess bioequivalence and bioavailability.
Why It Matters
Optimizing oral semaglutide formulation could significantly impact patient adherence and reduce manufacturing costs. A more bioavailable oral semaglutide tablet would allow for lower active ingredient doses, potentially minimizing side effects and improving tolerability. This could expand access to GLP-1R agonist therapy for Type 2 Diabetes Mellitus patients who prefer non-injectable options. If successful, this research could lead to a more efficient and patient-friendly oral semaglutide protocol, potentially altering current dosing strategies and making this highly effective peptide more accessible and convenient for daily use.
semaglutide
oral formulation
type 2 diabetes
pharmacokinetics
bioavailability
clinical trial